STUDY QUESTION: Do patient-specific features contribute to the differences between measured serum anti-Müllerian hormone (AMH) concentrations and AMH values expected from the corresponding antral follicle count (AFC)?
Introduction
Ovarian stimulation by exogenous gonadotropins is a crucial step in IVF treatments aimed at achieving an adequate ovarian response (Broekmans et al., 2014) . Ovarian response, as measured by the number of oocytes retrieved, declines with increasing reproductive age due to a progressive diminishing of ovarian reserve (Hansen et al., 2008; Wallace and Kelsey, 2010) . However, there is a considerable inter-individual variability in ovarian reserve and consequently in ovarian response to stimulation even among women of the same chronological age (Fauser et al., 2008; Wallace and Kelsey, 2010; Fleming et al., 2015) . Therefore, the assessment of ovarian reserve is a matter of the utmost importance prior to an IVF cycle with ovarian stimulation as it allows identification of women at risk of poor or excessive ovarian response. Based on this assessment, appropriate counselling and individualized ovarian stimulation can be offered to patients in order to improve their safety and treatment efficacy (Broer et al., 2009; Nelson et al., 2009; Jayaprakasan et al., 2010; Fleming et al., 2015; La Marca and Sunkara, 2014) .
Antral follicle count (AFC), consisting of all ultrasonographically identified and counted antral follicles measuring 2-10 mm in diameter in both ovaries, and serum anti-Müllerian hormone (AMH) concentration are now generally accepted as the most reliable biomarkers for the assessment of ovarian reserve and prediction of ovarian response in terms of the number of oocyte retrieved (Broer et al., 2009; Nelson et al., 2009; Broekmans et al., 2010; Jayaprakasan et al., 2010; Iliodromiti et al., 2015) .
A strong positive correlation between AMH and AFC and paralleled fluctuations of AMH and AFC have been demonstrated throughout the regular menstrual cycle (Gnoth et al., 2015; Depmann et al., 2016; Schiffner et al., 2017) . These findings have been expected taking into account the fact that ultrasonographically identifiable small growing follicles included in the AFC are the main contributors to serum AMH concentration (Weenen et al., 2004; Jeppesen et al., 2013) . However, it is not unusual for the IVF specialists to encounter a serum AMH level that is higher or lower than expected according to AFC, even when both measurement of AMH and counting of antral follicles are performed during the early follicular phase of the same menstrual cycle in a single clinical centre (Nelson, 2013; Nelson et al., 2015) . The findings of unexpectedly different serum AMH levels in patients with the same number of antral follicles may result in difficulties in pre-treatment patient counselling and ovarian stimulation planning and may also have clinical significance.
The observed discrepancies between measured AMH values and AMH values expected based on the corresponding AFC cannot be entirely explained by technical limitations of counting of antral follicles and analytical variability of the AMH assay used (Nelson, 2013; Fleming et al., 2015; Nelson et al., 2015) . This prompted us to hypothesize that measured serum AMH concentrations being higher or lower than expected reflect patient-specific actions of yetunrecognized factor(s) contributing to the difference in per-follicular AMH production between patients. Thus, this study aimed to investigate a potential association of clinical and biochemical parameters with the AMH-AFC discordances as defined by the differences between measured AMH values and AMH values predicted based on the corresponding AFC (AMHp), i.e. residual (RES AMH ). No study addressing this issue has been published so far.
Materials and Methods
Medical records of 1097 patients aged 20-44 years who underwent their first IVF cycle with a GnRH antagonist protocol between March 2011 and July 2013 were retrospectively analysed. The study population comprised of 705 (64.3%) women with normal ovarian morphology and 392 (35.7%) women with polycystic ovarian morphology (PCOM) (Balen et al., 2003) ( Table I ). The exclusion criteria were as follows: basal serum FSH concentration higher than 12 IU/L, hyperprolactinemia, non-classic congenital adrenal hyperplasia, thyroid dysfunction, diabetes, endometriosis, pelvic surgery, previous ovarian surgery, unilateral oophorectomy, abnormal ultrasound scan defined as the presence of an ovarian mass or at least one follicle with diameter >9 mm, and use of medications that might have an influence on endocrine profile. Patients with FSH > 12 IU/L were excluded from the study as they did not have all of the data required for the analysis in their medical records due to a different initial infertility evaluation. Women with one ovarian follicle >9 mm in diameter were excluded from further analysis since blood sampling for determination of AMH and other hormones concentrations was not performed in the same menstrual cycle as the ultrasonographic examination in these patients.
Classification of patients
AMHp values were calculated using the linear regression equation (AMHp = −4.4 + 1.5 × AFC) describing the association between AMH and AFC in the entire study population. The coefficients of determination (R 2 ) in the linear and quadratic regression models were equal (R 2 = 0.545) and greater compared to R 2 values in other tested regression models such as Log X (R 2 = 0.387) and Log Y (R 2 = 0.528). The linear regression equation was chosen as being more intuitive than the quadratic regression. Patients were classified into two groups according to the direction of deviation of measured AMH from AMHp. The higher-than-predicted (HTP) group comprised patients with AMH higher than AMHp (N = 466) and the lower-than-predicted (LTP) group comprised patients with AMH lower than AMHp (N = 631). The absolute value of RES AMH was considered to be the measure of the degree of AMH-AFC agreement.
Clinical investigation
Ultrasonographic examinations were performed during the early follicular phase of the menstrual cycle in compliance with recommendation given by Broekmans et al. (2010) . The number of follicles in each ovary was assessed by a single investigator (M.Š.A.) using the same ultrasound equipment with a 2D transvaginal probe 5-7 MHz (Toshiba, Nemio, Japan) within the investigation period, as described previously (Dewailly et al., 2014) . PCOM was defined as the presence of > 11 follicles measuring 2-9 mm in diameter (AFC) in at least one ovary, in agreement with Balen et al. (2003) and with our recent data using transvaginal ultrasound equipped with a 5-7 MHz transducer (Dewailly et al., 2014) .
Anthropometric measurements were performed and BMI was calculated on the same day as the transvaginal ultrasound scan. Data on menstrual cycle length (MCL) were collected by using the set of uniform questions as described elsewhere (Alebić et al., 2016) . Oligo-or amenorrhoea (OA) was defined as the mean MCL being > 35 days in the preceding year.
Laboratory analyses
Blood sample collections for biochemistry analyses were performed in the early follicular phase of the same menstrual cycle as the transvaginal ultrasound scan (i.e. days 3-5 of a spontaneous menstrual cycle or a withdrawal bleeding induced by micronized progesterone or didrogesterone) between 7:30 and 9:30 h after an overnight fast. Estradiol (E 2 ), FSH, LH, testosterone (T) were determined by chemiluminescent immunoassays on the Access ® 2 analyzer (Beckman Coulter, Inc., Brea, USA). In our laboratory, the method performance characteristics including repeatability, intermediate precision and within-laboratory precision were verified by following CLSI EP15-A2 Guidelines (Clinical and Laboratory Standards Institute, 2005) . The coefficients of variation for intra-assay precision (repeatability), the inter-assay precision (intermediate precision) and within-laboratory precision of the E 2 , FSH, LH and T assays were as follows: 6.0, 3.4, 6.0%; 2.9, 3.4, 3.9%; 4.2, 2.7, 5%; and 3.6, 2.3, 3.8%. Serum AMH concentration was determined using the original protocol of the AMH Gen II ELISA (Beckman Coulter, Inc., Brea, USA). The intraand inter-assay imprecision and within-laboratory imprecision of the AMH Gen II ELISA assessed using two levels of commercial control materials were as follows: 2.5, 1.5 and 2.5% (Control I, 19.2 pmol/L) and 4.0, 2.3 and 4.0% (Control II, 63.6 pmol/L), respectively.
All samples for determination of AMH concentration were obtained under the same pre-analytical condition (sample collection, handling and storage). Sera were separated from the clot within 2 h of blood collection, aliquoted and stored at −25 to −20°C, for up to 14 days, until analysed. In this study, we avoided inter-operator, inter-procedure and interlaboratory differences in the AMH measurements as all analyses were performed by a single highly skilled technician using certified laboratory equipment and the same method procedure in a single laboratory. In addition, we had implemented the manufacturer's recommendation on analytical conditions in full. Evaluation of the impact of the pre-mix protocol on the AMH results obtained in our laboratory using standardized preanalytical procedure demonstrated that the AMH results obtained using the modified protocol are~2-fold higher than those obtained using the original protocol, with an excellent correlation coefficient (r = 0.989, data not shown).
All biochemistry analyses were performed in a single laboratory accredited according to EN ISO 15189: Medical laboratories-Requirements for quality and competence. was used for statistical analysis. Patient characteristics were compared between the groups by using Mann-Whitney test. P < 0.05 was considered statistically significant. Univariate linear regression analysis was used to assess the relationship between AMH and AFC. Spearman test was used to identify patient characteristics associated with RES AMH in the LTP group and HTP group, respectively. Multiple regression analysis (MRA) with stepwise selection was performed to disclose potential confounders in the association between RES AMH and patient characteristics in both groups. Chi-quadrat test was used to compare the proportions of patients between the groups. Logistic regression was used to investigate patient characteristics associated with an increased probability of HTP or LTP deviation. for their data to be used for clinical research, statistical reports and/or educational purposes.
Statistical analysis

Results
Clinical and biochemical characteristics of women with normal ovarian morphology (non-PCOM) and women with PCOM included in the study are presented in Table I AMH was strongly correlated to AFC in the entire study population (regression equation: AMH = −4.4 + 1.5 × AFC; r = 0.732, P < 0.001). In Fig. 1 , AMH values above the regression line (i.e. higher than AMHp) are depicted as squares (HTP group, n = 466) and AMH values below the regression line (i.e. lower than AMHp) are depicted as circles (LTP group, n = 631). The clinical and biochemical characteristics of the entire study population and the groups formed according to RES AMH are presented in Table II . Patients in the HTP group had significantly longer MCL and higher AMH and LH concentrations but lower AFC and FSH than their counterparts in the LTP group. Significant positive or negative associations of absolute value of RES AMH with age, MCL, AFC, FSH and T were demonstrated in both groups (Table III) . LH and BMI were positively associated to the absolute values of RES AMH exclusively in the HTP and LTP group, respectively (Table III) . These parameters were further analysed using a stepwise MRA. In the HTP group, only one significant model was created (AFC + LH) explaining 30.4% of the variance of absolute value of RES AMH as the dependent variable (Table IV) . In the LTP group, four significant models were obtained (Table IV) . In both groups, AFC was the variable contributing the most to the variance of absolute value of RES AMH (28.7 and 39.9% in the HTP and LTP group, respectively).
The deviations of measured AMH values from the expected ones (AMHp) were in general higher in women with PCOM compared to women with normal ovarian morphology. Although the proportion of women with PCOM was higher in the LTP group than in the HTP group (60.7 vs 39.3%), the observed difference was not statistically significant (P = 0.111). There was no difference between the proportions of eumenorrhoeic women with PCOM and oligo/amenorrhoeic women with PCOM in the HTP group (55.8 vs 44.2%; P = 0.147) while a majority of PCOM patients were eumenorrhoeic in the LTP group (69.3 vs 30.7%; P < 0.001). However, the probability for a PCOM patient to have an AMH level higher than predicted grows with an increase in LH (OR = 1.09; 95% CI: 1.02-1.15) and a decrease in FSH (OR = 0.79; 95%CI: 0.70-0.90). The non-PCOM women were also evenly distributed between the HTP group and the LTP group (44.3 vs 55.7%, P = 0.111).
Discussion
This study is the first attempt to explore patient characteristics as variables potentially contributing to the observed differences (RES AMH ) between measured serum AMH levels and AMH values expected according to the corresponding AFC. These differences could be attributed to well-known disadvantages of AFC assessment such as a tendency to overcount the number of antral follicles due to potential inclusion of atretic follicles and other ovarian sonolucencies in the sum of antral follicles, scanning difficulties associated with overweight, or inter-cycle variation of AFC. In addition, there are some practical issues such as inter-observer variations and recounting of follicles that have already been identified as they both increase with an increased AFC Fleming et al., 2015; Nelson et al., 2015) . Indeed, in our study, AFC was identified as the variable with the strongest association to RES AMH and the biggest contribution to the variability of RES AMH in both groups.
However, our data indicate that miscounting of the antral follicles is not the sole explanation for the observed RES AMH. We have found that HTP patients had a significantly longer MCL and higher serum AMH and LH levels but lower AFC and serum FSH levels compared to LTP patients. Although, longer MCL does not necessarily indicate PCOS, the presence of oligomenorrhoea (defined by the average MCL longer than 35 days in the previous year), together with a high serum AMH level, which has emerged as the biochemical marker of PCOM, may be considered indicative for PCOS (Pigny et It has been previously shown that increased AMH levels in PCOS are not only due to the follicle excess but also due to hyperactive granulosa cells (Pellatt et al., 2007) , thus explaining positive RES AMH values. In addition, higher serum AMH levels have been found in women with PCOM than in women with normal ovarian morphology, being higher in oligo/anovulatory than in ovulatory women with PCOM (Pigny et al., 2006; Pellatt et al., 2007; Catteau-Jonard et al., 2012) . Likewise, the average per-follicle AMH production and serum LH level were identified as independent variables positively associated with MCL in patients with PCOS (Alebić et al., 2015) . However, granulosa cell hyperactivity cannot be extrapolated to eumenorrhoeic non-PCOM patients to explain serum AMH values higher or lower than expected based on the corresponding AFC. Indeed, we found that the expected AMH values in oligo/amenorrhoeic women with PCOM were higher than in eumenorrhoeic women with PCOM or normal ovarian morphology for the given AFC, indicating a bigger contribution of each follicle to the total ovarian AMH output (results not shown). Although, we had expected to find the majority of oligo/amenorrhoeic women with PCOM in the HTP group, there was no difference in the proportion of oligo/amenorrhoeic PCOM women between the HTP group and LTP group. This unexpected distribution can be explained by the definition AMHp values which were calculated using the linear regression equation (AMHp = −4.4 + 1.5 × AFC) describing the association between AMH and AFC in the entire study population. Since the oligo/ amenorrhoeic women with PCOM women had higher AFCs than other women, their AMHp were equally distributed below and above the respective regression line. This also explains preferential distribution of eumenorrhoeic patients with PCOM to the LTP group, thus leading to an AFC range paradoxically lower in the HTP than in the LTP group while the range of the serum AMH levels was higher. However, the presence of PCOS and PCOM is not the sole explanation for positive or negative RES AMH values since non-PCOS and non-PCOM women were also included in the HTP and LTP groups, respectively. As shown by our MRA, AFC remains the most important contributor to the variance of RES AMH values. Whether this is through solely technical reasons (as discussed above) and/or through some features inherent to the patients cannot be addressed by our study. It would be interesting to check whether this contribution of AFC is weaker when technologically newer ultrasound devices are used.
The intra-menstrual cycle and inter-menstrual cycle AMH variations may contribute to the AMH-AFC discordance (Wunder et al., 2008; Hadlow et al., 2016) . However, in our clinical setting with simultaneous determination of AMH and AFC in the early follicular phase of menstrual cycle, the effects of these variations were likely very small.
Interestingly, MRA showed that in the HTP group, only LH was significantly related to RES AMH , independently from AFC. This is in line with previous reports showing a positive correlation between serum LH and AMH levels Pigny et al., 2006) , coefficient of determination; P < 0.05 was considered statistically significant; NS, non-significant. not from controls and ovulatory PCOS women) (Pellatt et al., 2007) and/or from AMH stimulation of GnRH-dependent LH pulsatility and secretion as demonstrated in mice (Cimino et al., 2016) . Although the PCOS phenotype was not found associated with the direction of deviation of measured AMH from AMHp after MRA, the Spearman test showed that serum LH levels were correlated with the absolute value of RES AMH only in oligo/amenorrhoeic PCOM women with AMH higher than predicted (data not shown), suggesting that this relationship is specific for women with PCOS. This is in line with the previously reported positive and independent relationship between LH and AMH exclusively in PCOS populations (Catteau-Jonard et al., 2007) .
In the LTP group, several patient variables were found associated to RES AMH , independently from AFC. Each of them added significant benefit to the models yielded by the MRA. According to our results, at any given AFC, the negative value of RES AMH will increase along with the increment in serum FSH level and BMI value and with shortening of MCL and the decrement in serum T level. The clinical and biological correlates (MCL, FSH, T) to RES AMH values in the LTP group suggest the occurrence of impaired AMH production due to defective granulosa cells for various reasons such as age, overweight/obesity and/or other unknown factors, at least in some patients. Conflicting reports have been published on the effect of BMI on serum AMH concentration (La Marca et al., 2013) but recent studies converge towards a negative effect, albeit weak (Cui et al., 2014; Lefebvre et al., 2017) .
Our findings have limitations and strengths. The strength of our study is the use of data from ethnically and racially homogenous women who underwent a harmonized pre-treatment evaluation for IVF in a single clinical centre. The assessment of AFC in the entire study population was performed by the same experienced, reproductive medicine specialist using the same ultrasound equipment under strictly standardized conditions designed to reduce technical limitation of counting of antral follicles and observer-dependent variations. Since both AFC assessments and determinations of AMH concentration were performed during the early follicular phase of menstrual cycle, it cannot be excluded that the evaluation day might have impacted on the values of AFC as well as on the measured AMH levels, especially in the LTP group of women through the earlier initiation of follicular growth (Klein et al., 2002; van Zonneveld et al., 2003) . Using older ultrasounds could be seen as one of the limitations of the study as it may not provide a maximal resolution of ovarian follicles. However, we may presume that, if present, this technological interference was equally effective throughout the period of investigation.
One limitation of our study is the patient selection that precludes generalization of the results to women of different geographic origin, ethnicity, race or reproductive status. We also acknowledge that the FSH threshold selected could have an impact on the study outcomes. Additionally, AMH measurements were performed by the original AMH Gen II ELISA. However, this assay has demonstrated stable and acceptable analytical performance in our laboratory, as documented by internal quality control results, and the results of external quality assessment (UK NEQAS for Peptide Hormones, Edinburg, UK) over the entire period of its use. Consequently, the contribution of preanalytical and analytical assay-specific variation to the observed the AMH-AFC discordances is expected to be minimal and much lower than that of biological variation of AMH (van Disseldorp et al., 2010; Fleming et al., 2013; Hadlow et al. 2016 ). In conclusion, our data expand the explanation of AMH-AFC disagreements from the technical issues only toward patient-specific differences in follicular production of AMH. Such a hypothesis implies that AMH higher than AMHp could suggest up-regulated AMH secretion (a typical PCOS feature) while AMH lower than AMHp suggest down-regulated AMH secretion that could be seen as an early symptom of diminished ovarian reserve and premature ovarian insufficiency. In other words, when challenged against AFC, the serum AMH level is not only a quantitative but also a qualitative follicle marker, in relation with clinical and endocrine parameters. Further research is needed to investigate the clinical relevance of AMH-AFC discordances suggesting variation in per-follicle AMH production.
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